ANTIGLAUCOMATOUS ACTIVITY OF BETAXOLOL CHLORHYDRATE SORBED ONTO DIFFERENT ISOBUTYLCYANOACRYLATE NANOPARTICLE PREPARATIONS

被引:69
作者
MARCHALHEUSSLER, L
MAINCENT, P
HOFFMAN, M
SPITTLER, J
COUVREUR, P
机构
[1] FAC SCI PHARMACEUT & BIOL NANCY,PHARM GALEN LAB,5 RUE A LEBRUN,BP 403,F-54001 NANCY,FRANCE
[2] LABS ALCON POS,KAYSERSBERG,FRANCE
[3] CNRS,PHARM GALEN & BIOPHARM LAB,UA 1218,PARIS 11,FRANCE
关键词
Betaxolol chlorhydrate; Glaucoma; Glaucomatous rabbit; Isobutylcyanoacrylate nanoparticle; Ophthalmic drug delivery system;
D O I
10.1016/0378-5173(90)90248-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objectives of the present work were to evaluate the effects, on the reduction of the intra-ocular pressure (IOP) in glaucomatous rabbits, of different physico-chemical parameters such as: (1) the adsorption percentage of an antiglaucomatous drug (betaxolol chlorhydrate) onto isobutylcyanoacrylate nanoparticles; (2) the binding type of the drug onto the surface of the particles (hydrophobic or electrostatic). By modification of the surface charge, it was possible to adsorb either 25, 30 or 70% for the same drug concentration. When administered in glaucomatous rabbits, in comparison with commercial eye drops, the suspension with the highest adsorption level considerably lowered the overall therapeutic activity. The suspension with the lowest drug payload did not significantly increase the maximal intensity of the therapeutic response and tended to prolong the reduction of the IOP in time. It has been clearly shown that, regarding the ocular administration, the surface charge of the particles and the binding type of the drug onto the nanoparticles were much more important parameters than the drug adsorption percentage onto the nanoparticles. © 1990.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 13 条
[1]  
Couvreur P, 1982, US patent, Patent No. [4329332 A, 4329332]
[2]   PARTICLE-SIZE AND SIZE DISTRIBUTION OF POLY(BUTYL 2-CYANOACRYLATE) NANOPARTICLES .2. INFLUENCE OF STABILIZERS [J].
DOUGLAS, SJ ;
ILLUM, L ;
DAVIS, SS .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1985, 103 (01) :154-163
[3]   A GAMMA-SCINTIGRAPHIC EVALUATION OF MICROPARTICULATE OPHTHALMIC DELIVERY SYSTEMS - LIPOSOMES AND NANOPARTICLES [J].
FITZGERALD, P ;
HADGRAFT, J ;
KREUTER, J ;
WILSON, CG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 40 (1-2) :81-84
[4]   PHARMACOKINETICS AND DISTRIBUTION OF A BIODEGRADABLE DRUG-CARRIER [J].
GRISLAIN, L ;
COUVREUR, P ;
LENAERTS, V ;
ROLAND, M ;
DEPREZDECAMPENEERE, D ;
SPEISER, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1983, 15 (03) :335-345
[5]   QUANTITATION OF THE RELEASE OF DOXORUBICIN FROM COLLOIDAL DOSAGE FORMS USING DYNAMIC DIALYSIS [J].
GUPTA, PK ;
HUNG, CT ;
PERRIER, DG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (02) :141-145
[6]   ENHANCEMENT OF THE MYOTIC RESPONSE OF RABBITS WITH PILOCARPINE-LOADED POLYBUTYLCYANOACRYLATE NANOPARTICLES [J].
HARMIA, T ;
KREUTER, J ;
SPEISER, P ;
BOYE, T ;
GURNY, R ;
KUBIS, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 33 (1-3) :187-193
[7]  
ILLUM L, 1984, J PHARMACOL EXP THER, V3, P733
[8]   COMPARATIVE-STUDY ON THE CYTOSTATIC EFFECTS AND THE TISSUE DISTRIBUTION OF 5-FLUOROURACIL IN A FREE FORM AND BOUND TO POLYBUTYLCYANOACRYLATE NANOPARTICLES IN SARCOMA 180-BEARING MICE [J].
KREUTER, J ;
HARTMANN, HR .
ONCOLOGY, 1983, 40 (05) :363-366
[9]  
KREUTER J, 1988, 15TH P INT S CONTR R, P203
[10]  
MAINCENT P, 1986, J PHARM SCI, V10, P955